Enhance.MD vs Shed: Which Is Cheaper?
Released · Last reviewed
Both programmes priced at a standard therapeutic dose, with the subtraction shown for each molecule separately.
Which is cheaper: the arithmetic
Standard therapeutic dosing only. Each price was read on the program's own page on October 15, 2026; "all-in" adds any required membership. Each molecule is answered separately, because the two are priced differently at the same provider.
Tirzepatide: Shed at $239 a month ($2,868 a year) against Enhance.MD at $280 per 4-week cycle (13 charges a year, $3,640), each program's lowest all-in price. $3,640 − $2,868 = $772 across a year. Without committing to a longer plan, Enhance.MD is $329 per 4 weeks and Shed $299 a month.
Semaglutide: Shed at $159 a month ($1,908 a year) against Enhance.MD at $212 per 4-week cycle (13 charges a year, $2,756), each program's lowest all-in price. $2,756 − $1,908 = $848 across a year. Without committing to a longer plan, Enhance.MD is $249 per 4 weeks and Shed $199 a month.
Figures come from our published dataset (read 2026-10-15). Microdose tiers are excluded: they sit below every dose the pivotal trials studied. A lower price on a 3-, 6- or 12-month plan usually means paying for that term, and compounded medication is generally not refundable once shipped.
What the price does not tell you
Whether the dispensing pharmacy is named before purchase, which is the only verification available to you before money changes hands. What the cancellation terms are, and what is refundable once medication has shipped. Whether laboratory work is required and billed separately. And whether a clinician licensed in your state is available, which decides whether the programme can serve you at all.
Full profiles: Enhance.MD and Shed. Complete rankings at the semaglutide and tirzepatide comparison tables.
Compounded GLP-1 medicines are not FDA-approved and are not therapeutically equivalent to any brand-name product. This is consumer price research, not medical advice.
The numbers behind this page
How this comparison is kept current
Every price quoted in this comparison comes from the programme's own pricing page and carries the date it was captured. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
The figures in this comparison sit inside a market with a measurable shape, and that shape is what makes any single price readable.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.